Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,476Revenue $M640Net Margin (%)-19.9Altman Z-Score5.8
Enterprise Value $M4,058EPS $-0.9Operating Margin %-27.0Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-17.2Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %--Quick Ratio4.8Cash flow > EarningsY
Price/Sales6.95-y EBITDA Growth Rate %--Current Ratio5.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-126.3ROA % (ttm)-6.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-9.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M150ROIC % (ttm)-16.9Gross Margin Increase y-yY

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSVanguard Health Care Fund 2015-12-31 Reduce$57.89 - $80.14
($70.39)
$ 29.83-58%Reduce -0.40%6,851,996
ALKSKen Fisher 2015-12-31 Add$57.89 - $80.14
($70.19)
$ 29.83-58%Add 0.34%120,327
ALKSVanguard Health Care Fund 2015-09-30 Add0.08%$55.08 - $72.79
($66.01)
$ 29.83-55%Add 10.43%6,879,583
ALKSGeorge Soros 2015-09-30 Buy 0.01%$55.08 - $72.79
($66.01)
$ 29.83-55%New holding7,900
ALKSKen Fisher 2015-09-30 Add$55.08 - $72.79
($66.01)
$ 29.83-55%Add 11.90%119,920
ALKSVanguard Health Care Fund 2015-03-31 Add$58.24 - $73.64
($68.32)
$ 29.83-56%Add 0.05%6,229,583
ALKSVanguard Health Care Fund 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 29.83-42%Add 0.05%6,226,383
ALKSKen Fisher 2014-12-31 Add$40.23 - $58.88
($51.09)
$ 29.83-42%Add 10.18%107,164
ALKSVanguard Health Care Fund 2014-09-30 Add0.01%$41.54 - $51.75
($44.82)
$ 29.83-33%Add 1.42%6,223,083
ALKSKen Fisher 2014-09-30 Add$41.54 - $51.52
($44.73)
$ 29.83-33%Add 75.86%97,264
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 29.83-35%Add 18.45%6,135,913
ALKSKen Fisher 2014-06-30 Buy 0.01%$41.1 - $50.94
($46.06)
$ 29.83-35%New holding55,309
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 29.83-37%Add 41.07%5,180,238
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 29.83-19%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 29.83-8%Add 26.21%2,864,896
ALKSJoel Greenblatt 2013-09-30 Sold Out -0.03%$28.66 - $35.35
($32.58)
$ 29.83-8%Sold Out0
ALKSVanguard Health Care Fund 2013-06-30 Add0.11%$22.35 - $33.72
($29.15)
$ 29.832%Add 84.09%2,269,902
ALKSJoel Greenblatt 2013-06-30 Buy 0.03%$22.35 - $33.72
($29.15)
$ 29.832%New holding26,624
ALKSVanguard Health Care Fund 2013-03-31 Add0.04%$18.52 - $23.81
($21.87)
$ 29.8336%Add 47.24%1,233,024
ALKSVanguard Health Care Fund 2012-06-30 Add$15.12 - $18.64
($16.96)
$ 29.8376%Add 6.28%837,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MITCHELL PAUL JDirector 2016-02-04Sell2,000$32.81-9.08view
MITCHELL PAUL JDirector 2016-01-04Sell2,000$77.33-61.43view
BREYER ROBERT ADirector 2016-01-04Sell2,000$77.33-61.43view
Stejbach MarkChief Commercial Officer 2015-12-28Sell10,000$80.24-62.82view
Cooke ShanePresident, Alkermes plc 2015-12-23Sell18,000$77.23-61.38view
POPS RICHARD FDirector and CEO, Alkermes plc 2015-12-07Sell37,500$72.06-58.6view
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc. 2015-12-07Sell3,750$73.02-59.15view
Stejbach MarkChief Commercial Officer 2015-12-01Sell18,000$72.18-58.67view
POPS RICHARD FDirector and CEO, Alkermes plc 2015-12-01Sell50,000$72.29-58.74view
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc. 2015-12-01Sell10,000$72.18-58.67view

Quarterly/Annual Reports about ALKS:

    News about ALKS:

    Articles On GuruFocus.com
    AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
    Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
    Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
    Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
    Opportunistic Coat-tailing Jan 05 2010 
    Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 

    More From Other Websites
    Who Will Come Out On Top As Flu Season Draws Down Feb 10 2016
    Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia Feb 10 2016
    7:00 am Alkermes initiates ENLIGHTEN-2, the second of two core phase 3 studies for ALKS 3831, an... Feb 10 2016
    Alkermes CEO Richard Pops Isn't Giving Up On Breakthrough Depression Drugs Feb 09 2016
    Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
    Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences Feb 02 2016
    Alkermes short bets built up ahead of depression drug setback Jan 28 2016
    Alkermes Initiates Early-Stage Study on Alzheimer's Drug Jan 27 2016
    Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
    Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
    Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119 Jan 25 2016
    8 Things That Could Lift Biotech Stocks Out of Bear Market Jan 24 2016
    4 Stocks That Punished Shareholders Last Week Jan 23 2016
    Alkermes Hit 52-Week Low on Unfavorable Phase III Data Jan 22 2016
    Alkermes Learns Makeovers Aren't Easy Jan 22 2016
    [$$] Business Watch Jan 21 2016
    Why These 5 Stocks Are Plummeting Today Jan 21 2016
    [$$] Alkermes Depression Drug Disappoints Jan 21 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK